1st line Panitumumab plus FOLFIRI or FOLFOX for patients with RAS wildtype metastatic colorectal cancer in Germany: Interim results of the non-interventional study VALIDATE Posted on 22. September 20204. November 2020 by Silke Grassl Autoren: Uhlig J., Potenberg J., Semsek D., Stuebs P., Fichter C., Koehler A., Mueller L., Reiser M., Siebenbach H., Goehler T., Jacobasch D., Schneider-Kappus W., Timm B., Potthoff K., Marschner N. ESMO 2020 (Abstract)
